UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM10-Q
(Mark One)
| ☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended March 31, 2017
OR
| ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission File Number:0-21990
Mateon Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 13-3679168 | |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
701 Gateway Blvd, Suite 210
South San Francisco, CA 94080
(Address of principal executive offices, including zip code)
(650) 635-7000
(Registrant’s telephone number, including area code)
Not applicable
(Former name, former address and former fiscal year, if changed since last report)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 ofRegulation S-T (§232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, anon-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule12b-2 of the Exchange Act inRule 12b-2 of the Exchange Act.
| Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
| Non-accelerated filer | ☐ (Do not check if a smaller reporting company) | Smaller reporting company | ☒ | |||
| Emerging Growth Company | ☐ | |||||
Indicate by check mark whether the registrant is a shell company (as defined inRule 12b-2 of the Exchange Act). Yes ☐ No ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
As of May 8, 2017, there were 26,544,934 shares of the Registrant’s Common Stock issued and outstanding.
Mateon Therapeutics, Inc.
Cautionary Factors that May Affect Future Results
This report contains “forward-looking statements,” which give management’s current expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historic or current facts. They use words, such as “may,” “will,” “would,” “expect,” “plan,” “anticipate,” “could,” “project,” “believe,” “estimate,” “potential,” “seek,” “indicate,” or “continue” or the negative of these terms and other words and terms of similar meaning.
Any or all of our forward-looking statements in this report may turn out to be wrong. They can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. Consequently, no forward-looking statement can be guaranteed. Actual results may vary materially from those set forth in forward-looking statements. Forward-looking statements include, but are not limited to, statements regarding our or our management’s expectations, hopes, beliefs, intentions or strategies regarding the future, such as our estimates regarding the initiation, timing, progress and results of our preclinical and clinical trials; anticipated operating losses, future performance, future revenues and projected expenses; our liquidity and our expectations regarding our needs for and ability to raise additional capital; our ability to select and capitalize on commercially desirable product opportunities as a result of limited financial resources; our ability to manage our expenses effectively and raise the funds needed to continue our business; our ability to retain the services of our current executive officers, directors and principal consultants; the competitive nature of our industry and the possibility that our product candidates may become obsolete; our ability to obtain and maintain regulatory approval of our product candidates and any future products we may develop; the clinical development of and the process of commercializing CA4P, which is also known as combretastatinA4-phosphate, fosbretabulin or fosbretabulin tromethamine; the efficacy of the combination of CA4P with bevacizumab; research and development programs including preclinical studies; regulatory and legislative developments in the United States and foreign countries; the timing, costs and other limitations involved in obtaining regulatory approval for any product candidate; the further preclinical or clinical development and commercialization of our product candidates; our ability to obtain and maintain orphan drug exclusivity for some of our product candidates; the potential benefits of our product candidates over other therapies; our ability to enter into and maintain any collaboration with respect to product candidates; our ability to continue to develop or commercialize our product candidates in the event any license agreements in place with third parties expire or are terminated; the performance and conduct of third parties, including our third-party manufacturers and third party service providers used in our clinical trials; our ability to obtain and maintain intellectual property protection for our product candidates and any future products we may develop and operate our business without infringing upon the intellectual property rights of others; the potential liability exposure related to our product candidates and any future products we may develop and our insurance coverage for such exposure; the size and growth of the potential markets for our products and our ability to serve those markets; the rate and degree of market acceptance of any future products; the sufficiency of potential proceeds from any financing; the volatility of the price of our common stock; the ability to achieve secondary trading of our stock in certain states; the dilutive effects of potential future equity issuances; our expectation that no dividends will be declared on our common stock in the foreseeable future; our ability to maintain an effective system of internal controls; the payment and reimbursement methods used by private or governmental third-party payers; our ability to retain adequate staffing levels; unfavorable global economic conditions; a failure of our internal computer systems or those of our contractors and consultants; potential misconduct or other improper activities by our employees, contractors or consultants; the ability of our business continuity and disaster recovery plans to protect us in the event of a natural disaster, and other factors discussed in our Annual Report on Form10-K for the year ended December 31, 2016 filed with the Securities and Exchange Commission (the SEC) on March 30, 2017 or any document incorporated by reference herein or therein.
We will not update forward-looking statements, whether as a result of new information, future events or otherwise, unless required by law. You are advised to consult any further disclosures we make in our reports to the SEC, including our reports on Form10-Q,8-K and10-K. Our filings list various important factors that could cause actual results to differ materially from expected results. We note these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider any such list to be a complete set of all potential risks or uncertainties.
2
INDEX
3
PART I - FINANCIAL INFORMATION
Condensed Balance Sheets
(in thousands, except per share data)
| March 31, 2017 | December 31, 2016 | |||||||
| (Unaudited) | (See Note 1) | |||||||
| ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 6,041 | $ | 3,535 | ||||
Short-term investments | 2,303 | 8,512 | ||||||
Prepaid clinical trial expenses | 1,542 | 1,946 | ||||||
Other prepaid expenses and current assets | 248 | 77 | ||||||
|
|
|
| |||||
Total current assets | 10,134 | 14,070 | ||||||
Property and equipment, net | 8 | 11 | ||||||
Other assets | 33 | 33 | ||||||
|
|
|
| |||||
Total assets | $ | 10,175 | $ | 14,114 | ||||
|
|
|
| |||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 312 | $ | 310 | ||||
Accrued compensation and employee benefits | 488 | 842 | ||||||
Accrued clinical trial expenses | 62 | 64 | ||||||
Other accrued liabilities | 531 | 398 | ||||||
|
|
|
| |||||
Total current liabilities | 1,393 | 1,614 | ||||||
|
|
|
| |||||
Commitments and contingencies | ||||||||
Stockholders’ equity: | ||||||||
Preferred stock, $0.01 par value, 15,000 shares authorized; | ||||||||
No shares issued and outstanding | — | — | ||||||
Common stock, $0.01 par value, 70,000 shares authorized; | ||||||||
26,545 shares issued and outstanding | 265 | 265 | ||||||
Additionalpaid-in capital | 290,938 | 290,698 | ||||||
Accumulated deficit | (282,421 | ) | (278,463 | ) | ||||
|
|
|
| |||||
Total stockholders’ equity | 8,782 | 12,500 | ||||||
|
|
|
| |||||
Total liabilities and stockholders’ equity | $ | 10,175 | $ | 14,114 | ||||
|
|
|
| |||||
See accompanying notes.
4
Condensed Statements of Comprehensive Loss
(in thousands, except per share data)
(unaudited)
| Three months ended March 31, | ||||||||
| 2017 | 2016 | |||||||
Operating expenses: | ||||||||
Research and development | $ | 2,848 | $ | 1,980 | ||||
General and administrative | 1,122 | 1,372 | ||||||
|
|
|
| |||||
Total operating expenses | 3,970 | 3,352 | ||||||
|
|
|
| |||||
Loss from operations | (3,970 | ) | (3,352 | ) | ||||
Interest income | 14 | 28 | ||||||
Other expense | (2 | ) | (1 | ) | ||||
|
|
|
| |||||
Net loss and comprehensive loss | $ | (3,958 | ) | $ | (3,325 | ) | ||
|
|
|
| |||||
Basic and diluted net loss per share attributable to common stock | $ | (0.15 | ) | $ | (0.13 | ) | ||
|
|
|
| |||||
Weighted-average number of common shares outstanding | 26,545 | 26,545 | ||||||
|
|
|
| |||||
See accompanying notes.
5
Condensed Statements of Cash Flows
(in thousands)
(unaudited)
| Three months ended March 31, | ||||||||
| 2017 | 2016 | |||||||
Operating activities: | ||||||||
Net loss | $ | (3,958 | ) | $ | (3,325 | ) | ||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Depreciation | 3 | 5 | ||||||
Stock-based compensation | 240 | 192 | ||||||
Changes in operating assets and liabilities: | ||||||||
Prepaid expenses and other current assets | 233 | (1,192 | ) | |||||
Accounts payable and accrued expenses | (221 | ) | (79 | ) | ||||
|
|
|
| |||||
Net cash used in operating activities | (3,703 | ) | (4,399 | ) | ||||
|
|
|
| |||||
Investing activities: | ||||||||
Purchase of short-term investments | — | (12,610 | ) | |||||
Sale of short-term investments | 6,209 | — | ||||||
|
|
|
| |||||
Net cash provided by (used in) investing activities | 6,209 | (12,610 | ) | |||||
|
|
|
| |||||
Increase (decrease) in cash and cash equivalents | 2,506 | (17,009 | ) | |||||
Cash and cash equivalents at beginning of period | 3,535 | 30,031 | ||||||
|
|
|
| |||||
Cash and cash equivalents at end of period | $ | 6,041 | $ | 13,022 | ||||
|
|
|
| |||||
See accompanying notes.
6
Notes to Condensed Financial Statements
March 31, 2017
(Unaudited)
| 1. | Summary of Significant Accounting Policies |
Description of Business
Mateon Therapeutics, Inc. (“Mateon” or the “Company”) is a clinical-stage biopharmaceutical company seeking to realize the full potential of vascular targeted therapy in oncology. Vascular targeted therapy includes vascular disrupting agents (VDAs), such as the investigational drugs that Mateon is developing, and anti-angiogenic agents (AAs), a number of which are approved and widely used in oncology indications. Mateon’s VDAs selectively obstruct a tumor’s blood supply without obstructing the blood supply to normal tissues, and treatment with Mateon’s VDAs has been shown to lead to significant central tumor necrosis. The Company believes that the treatment of cancer would be significantly improved if VDAs and AAs were used together, due to their complementary mechanisms of action. In combination, the VDA would occlude the blood vessels in the interior of a tumor while the AA would prevent the formation of new tumor blood vessels. The Company has two VDA drug candidates currently being tested in clinical trials, CA4P (combretastatin A4 phosphate, or fosbretabulin) and OXi4503. The Company was originally incorporated under the name OXiGENE, Inc. in 1988 in the state of New York, reincorporated in 1992 in the state of Delaware and changed its name to Mateon Therapeutics, Inc. on June 17, 2016.
Basis of Presentation
The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and with the instructions to Form10-Q and Article 10 ofRegulation S-X. The financial statements do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In the opinion of management, however, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2017 are not necessarily indicative of the results that may be expected for any other interim period or for the year ending December 31, 2017.
The balance sheet at December 31, 2016 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. For further information, refer to the financial statements and footnotes thereto included in the Annual Report on Form10-K for the Company for the year ended December 31, 2016.
Use of Estimates
The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from those estimates.
Cash Equivalents
Highly liquid investments with original maturities of three months or less at the date of purchase are considered to be cash equivalents. Cash equivalents are stated at fair value.
Short-term Investments
All marketable securities have been classified as “available for sale” and are carried at fair value, based upon quoted market prices. The Company considers itsavailable-for-sale portfolio to be available for use in current operations. Accordingly, the Company classifies certain investments as short-term marketable securities, even though the stated maturity date may be one year or more beyond the current balance sheet date. Unrealized gains and losses, net of any related tax effects, are excluded from earnings and are included in other comprehensive income and reported as a separate component of stockholders’ deficit until realized. Realized gains and losses and declines in value judged to be other than temporary, if any, onavailable-for-sale securities are included in other income (expense), net. The cost of securities sold is based on the specific-identification method.
Going Concern Evaluation
The Company has experienced net losses every year since inception and, as of March 31, 2017, had an accumulated deficit of over $282 million. The company has no source of revenue and does not expect to receive any product revenue in the near future. The Company expects to incur significant additional operating losses over at least the next several years, principally as a result of the Company’s continuing clinical trials for its investigational drugs. The principal source of the Company’s working capital to date has been the proceeds from the sale of equity. As of March 31, 2017, the Company had approximately $8.3 million in cash and short-term investments. Based on the Company’s planned operations, Management expects Mateon’s existing cash and short-term investments to support operations into October 2017. Prior to this time, the Company will need to secure additional funding or it could be forced to curtail or terminate operations. Because the Company does not currently have a guaranteed source of working capital that will sustain operations past October 2017, Management has determined that there is substantial doubt about the Company’s ability to continue as a going concern. The Company will need to raise capital in order to fund its operations beyond this date. If the Company is unable to access additional funds when needed, it may not be able to continue the development of its investigational drugs and the Company could be required to delay, scale back or eliminate some or all of its development programs and other operations. Any additional equity financing, if available to the Company, may not be available on favorable terms, would most likely be dilutive to its current stockholders and debt financing, if available, may involve restrictive covenants. If the Company accesses funds
7
through collaborative or licensing arrangements, it may be required to relinquish rights to some of its technologies or product candidates that it would otherwise seek to develop or commercialize on its own, on terms that are not favorable to the Company. The Company’s ability to access capital when needed is not assured and, if access is not achieved on a timely basis, will materially harm its business, financial condition and results of operations.
Recent Accounting Pronouncements
In February 2016, the FASB issued ASUNo. 2016-2, “Leases.” This ASU requires substantially all leases, including operating leases, to be recognized by lessees on their balance sheet as aright-of-use asset and corresponding lease liability. This ASU is effective for the Company’s interim and annual reporting periods beginning January 1, 2019 and early adoption is permitted. The Company is currently evaluating the impact that the adoption of this ASU will have on its financial statements.
In March 2016, the FASB issued ASUNo. 2016-09, “Improvements to Employee Share-Based Payment Accounting,” which simplified several aspects of the accounting for share-based payments, including immediate recognition of all excess tax benefits and deficiencies in the income statement, changing the threshold to qualify for equity classification up to the employees’ maximum statutory tax rates, allowing an entity-wide accounting policy election to either estimate the number of awards that are expected to vest or account for forfeitures as they occur, and clarifying the classification on the statement of cash flows for the excess tax benefit and employee taxes paid when an employer withholds shares fortax-withholding purposes. This ASU became effective for Mateon’s interim and annual reporting periods beginning January 1, 2017, and the adoption of this standard did not have a material impact on the Company’s financial statements. As part of the adoption of this standard, the Company elected to continue estimating the expected option forfeiture rate.
| 2. | Cash, Cash Equivalents, and Short-Term Investments |
Cash, cash equivalents and short-term investments consisted of the following (in thousands):
| March 31, 2017 | ||||||||||||||||
| Amortized Cost | Unrealized Gain | Unrealized (Loss) | Estimated Fair Value | |||||||||||||
Cash | $ | 654 | $ | — | $ | — | $ | 654 | ||||||||
Money market funds | 5,387 | — | — | 5,387 | ||||||||||||
U.S. government treasury bills | 601 | — | — | 601 | ||||||||||||
Corporate bonds and commercial paper | 1,702 | — | — | 1,702 | ||||||||||||
|
|
|
|
|
|
|
| |||||||||
| $ | 8,344 | $ | — | $ | — | $ | 8,344 | |||||||||
|
|
|
|
|
|
|
| |||||||||
Reported as: | ||||||||||||||||
Cash and cash equivalents | $ | 6,041 | ||||||||||||||
Short-term investments | 2,303 | |||||||||||||||
|
| |||||||||||||||
Total cash, cash equivalents and short-term investments | $ | 8,344 | ||||||||||||||
|
| |||||||||||||||
As of March 31, 2017, the Company’s cash equivalents and short-term investments had a weighted-average time to maturity of less than six months, and the Company has the ability to hold its investments through their maturity dates. There have been no significant realized gains or losses on investments for the period presented.
| 3. | Fair Value Measurements |
Fair value is defined as the price at which an asset could be exchanged or a liability transferred in a transaction between knowledgeable, willing parties in the principal or most advantageous market for the asset or liability. Where available, fair value is based on observable market prices or parameters or derived from such prices or parameters. Where observable prices or parameters are not available, valuation models are applied.
Assets and liabilities recorded at fair value are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities, are as follows:
Level 1—Inputs are unadjusted, quoted prices in active markets for identical assets at the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide reasonably accurate pricing information on an ongoing basis.
Level 2—Inputs, other than quoted prices included in Level 1, that are either directly or indirectly observable for the asset or liability through correlation with market data at the reporting date and for the duration of the instrument’s anticipated life.
The Company utilizes third party pricing services in developing fair value measurements where fair value is based on observable market inputs, including benchmark yields, reported trades, broker/dealer quotes, bids, offers and other reference data. The Company uses quotes from external pricing service providers and otheron-line quotation systems to verify the fair value of investments provided by third party pricing service providers.
8
Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities reflect management’s best estimate of what market participants would use in pricing the asset or liability at the reporting date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.
Financial assets measured at fair value on a recurring basis are categorized in the tables below based upon the lowest level of significant input to the valuations (in thousands):
| March 31, 2017 | ||||||||||||||||
| Level 1 | Level 2 | Level 3 | Total | |||||||||||||
Money market funds | $ | 5,387 | $ | — | $ | — | $ | 5,387 | ||||||||
U.S. government treasury bills | — | 601 | — | 601 | ||||||||||||
Corporate bonds and commercial paper | — | 1,702 | — | 1,702 | ||||||||||||
|
|
|
|
|
|
|
| |||||||||
Total | $ | 5,387 | $ | 2,303 | $ | — | $ | 7,690 | ||||||||
|
|
|
|
|
|
|
| |||||||||
| 4. | Stockholders’ Equity |
The following is a summary of the Company’s outstanding common stock warrants:
Expiration Date | Exercise Price | March 31, 2017 | December 31, 2016 | |||||||||
| (in thousands) | ||||||||||||
04/16/18 | $ | 3.40 | 1,460 | 1,460 | ||||||||
09/23/18 | $ | 2.80 | 147 | 147 | ||||||||
02/18/19 | $ | 2.75 | 1,872 | 1,872 | ||||||||
02/11/19 | $ | 2.56 | 293 | 293 | ||||||||
08/28/19 | $ | 2.90 | 2,700 | 2,700 | ||||||||
06/14/17 | $ | 3.70 | 216 | 216 | ||||||||
03/25/20 | $ | 1.71 | 2,920 | 2,920 | ||||||||
03/20/20 | $ | 2.13 | 234 | 234 | ||||||||
|
|
|
| |||||||||
Total Warrants Outstanding |
| 9,842 | 9,842 | |||||||||
|
|
|
| |||||||||
9
The following is a summary of the Company’s stock option activity under its equity incentive plans:
| Options Available for Grant | Options Outstanding | Weighted Average Exercise Price | Weighted Average Remaining Contractual Life | Aggregate Intrinsic Value | ||||||||||||||||
| (in thousands) | (years) | (in thousands) | ||||||||||||||||||
Balance at December 31, 2016 | 549 | 4,177 | $ | 1.47 | 8.14 | |||||||||||||||
Options authorized | 2,000 | |||||||||||||||||||
Options granted | (2,120 | ) | 2,120 | $ | 0.40 | |||||||||||||||
Options forfeited | 361 | (361 | ) | $ | 1.19 | |||||||||||||||
|
|
|
| |||||||||||||||||
Balance at March 31, 2017 | 790 | 5,936 | $ | 1.11 | 8.59 | $ | 933 | |||||||||||||
|
|
|
| |||||||||||||||||
Vested and exercisable at March 31, 2017 | 1,557 | $ | 1.68 | 7.64 | $ | 55 | ||||||||||||||
Vested and expected to vest at March 31, 2017 | 4,394 | $ | 1.04 | 8.41 | $ | 600 | ||||||||||||||
Unvested at March 31, 2017 | 4,379 | $ | 0.91 | |||||||||||||||||
As of March 31, 2017, there was approximately $1.4 million of unrecognized compensation cost related to stock option awards that is expected to be recognized as expense over a weighted average period of approximately 2.7 years.
The fair values for the stock options granted were estimated at the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions for the periods indicated:
| Three months ended March 31, | ||||||||
| 2017 | 2016 | |||||||
Risk-free interest rate | 2.0 | % | 1.5 | % | ||||
Expected life (years) | 6.3 | 6.0 | ||||||
Expected volatility | 89 | % | 89 | % | ||||
Dividend yield | 0 | % | 0 | % | ||||
| 5. | Net Loss Per Share |
Basic and diluted net loss per share was calculated by dividing the net loss per share attributed to the Company’s common shares by the weighted-average number of common shares outstanding during the period. Diluted net loss per share includes the effect of all dilutive, potentially issuable common equivalent shares as defined using the treasury stock method. All of the Company’s common stock equivalents are anti-dilutive due to the Company’s net loss position for all periods presented. Accordingly, common stock equivalents of approximately 5,936,000 stock options and 9,842,000 warrants at March 31, 2017 and 3,861,000 stock options and 9,842,000 warrants at March 31, 2016, were excluded from the calculation of weighted average shares for diluted net loss per share.
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis should be read together with the audited financial statements and notes in our Annual Report on Form10-K for the year ended December 31, 2016, as well as “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contained therein. The following discussion and analysis should also be read in conjunction with the unaudited financial statements set forth in Part I, Item 1 of this Quarterly Report on Form10-Q.
Overview
We are a biopharmaceutical company focused on the development of vascular disrupting agents, or VDAs, for the treatment of cancer. VDAs selectively target the vasculature of cancer tumors and obstruct a tumor’s blood supply without disrupting the blood supply to normal tissues. Treatment with VDAs has been shown to lead to significant central tumor necrosis, which refers to the death of cancer cells. Unlike most other drugs used for the treatment of cancer, our investigational drugs have consistently shown a stronger treatment effect in larger tumors than in smaller tumors.
10
VDAs are in a class of drugs called vascular targeted therapies, or VTTs, which also includes anti-angiogenic agents, or AAs. Bevacizumab (marketed under the brand name Avastin® by Roche/Genentech) and other currently-approved AA drugs work by preventing the growth of new blood vessels which can supply nutrients to tumor cells. We are seeking to realize the full potential of VTTs in oncology by using the combination of VDAs and AAs to treat cancer tumors. The aim of using a VDA and an AA in combination is for the VDA to directly cut off the blood supply to the majority of the tumor, while the AA indirectly inhibits angiogenesis, which is the process by which new blood vessels form andre-vascularize the tumor. Our current VDA development plans are focused on this combination so that the mechanism of action of each drug would complement that of the other – disrupting tumor blood supply in two different ways instead of just one.
We have two clinical stage investigational drugs, both VDAs, that we are currently developing – CA4P and OXi4503. Our most advanced compound is CA4P. The largest clinical trial of CA4P conducted to date was a phase 2 clinical trial in recurrent ovarian cancer sponsored by the Gynecologic Oncology Group, or GOG, which was completed in 2014 and met its primary endpoint by demonstrating an improvement in progression-free survival for the patients who received CA4P. This trial, referred to asGOG-0186I, compared treatment with CA4P plus bevacizumab to treatment with bevacizumab alone. Based on the positive results of this clinical trial, we are conducting the FOCUS Study, which is atwo-stage, phase 2/3 clinical trial in platinum-resistant ovarian cancer. FOCUS is comparing treatment with the three-drug combination of CA4P, bevacizumab and chemotherapy, or the active treatment arm, to treatment with the current standard of care, thetwo-drug combination of bevacizumab and chemotherapy, or the control arm. CA4P is also being studied in combination with pazopanib in anon-going phase 2 clinical trial in recurrent ovarian cancer that is sponsored by The Christie Hospital NHS Foundation Trust in the United Kingdom and a phase 1 study in combination with everolimus in neuroendocrine tumors that is sponsored by the Markey Cancer Center at the University of Kentucky. Our second compound, OXi4503, is being studied in combination with cytarabine in a phase 1/2 clinical trial in the United States in patients with relapsed or refractory acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS).
Recent Developments
On April 18, 2017, we announced results from the first scheduled interim analysis of theon-going FOCUS Study. The interim analysis was conducted after the first 20 patients enrolled into the trial had been treated for at least two months or had discontinued from the trial. Interim results indicated that no significant CA4P safety issues had been identified in the trial, and that the initial efficacy was in favor of CA4P, with 22% (2/9) of patients in the treatment arm responding compared to 9% (1/11) of patients in the control arm. As of May 8, 2017, we had enrolled approximately 40 patients into the FOCUS Study.
RESULTS OF OPERATIONS
Three months ended March 31, 2017 and 2016
Research and Development expenses
Research and development expenses increased for the three months ended March 31, 2017 compared to the same period in 2016 largely due to additional clinical trial activity related to our lead investigational drug, CA4P. The table below summarizes the most significant components of our research and development expenses for the periods indicated and provides the amount and percentage change in these components (in thousands):
| Three months ended March 31, | Change | |||||||||||||||
| 2017 | 2016 | Amount | % | |||||||||||||
Clinical studies | $ | 1,260 | $ | 817 | $ | 443 | 54 | % | ||||||||
Employee compensation and related | 964 | 709 | 255 | 36 | % | |||||||||||
Employee stock-based compensation | 105 | 88 | 17 | 19 | % | |||||||||||
Consulting and professional services | 197 | 229 | (32 | ) | -14 | % | ||||||||||
Drug manufacturing | 242 | 54 | 188 | 348 | % | |||||||||||
Other | 80 | 83 | (3 | ) | -4 | % | ||||||||||
|
|
|
|
|
|
|
| |||||||||
Total research and development | $ | 2,848 | $ | 1,980 | $ | 868 | 44 | % | ||||||||
|
|
|
|
|
|
|
| |||||||||
Higher expenses were incurred for clinical studies for the three months ended March 31, 2017 compared to the three months ended March 31, 2016 due to our phase 2/3 FOCUS study of CA4P in platinum-resistant ovarian cancer. FOCUS represents the most advanced clinical study for our lead investigational drug. We initiated this study in June 2016, and through March 31, 2017 had enrolled approximately 28 patients into the trial, significantly increasing costs for the 2017 period as compared to our incurring only planning costs for this trial during the 2016 period. The higher clinical study costs in 2017 associated with FOCUS were partially offset by lower clinical costs for a study of CA4P in neuroendocrine tumors, or NETs, which completed during 2016. Clinical study costs for OXi4503 in acute myeloid leukemia were similar in the two periods.
Employee compensation and related expenses increased for the three months ended March 31, 2017 compared to the three months ended March 31, 2016 due to severance incurred during the 2017 period as a result of a reduction in our development headcount in an area not directly related to the clinical trials. In addition, we hired an additional headcount in late 2016 to assist with recruitment of patients into the FOCUS study, also increasing costs for the 2017 period. Employee stock-based compensation increased for the three months ended March 31, 2017 compared to the three months ended March 31, 2016 due toone-year initial cliff vesting of stock options granted in March 2016, resulting in a reduction to the estimated forfeiture rates for this tranche, which increases expense, and the earlier timing of employee options grants during 2017.
11
Consulting and professional services decreased for the three months ended March 31, 2017 compared to the three months ended March 31, 2016 because we incurred planning costs with outside clinical experts for the FOCUS trial in platinum-resistant ovarian cancer during the 2016 period prior to the study’s initiation, and these were not required during 2017.
Timing of drug manufacturing costs is variable and is impacted by the timing of when drug product is needed for clinical trials, product expiration orre-test requirements, potential regulatory filings and scheduling of production batches based on the drug manufacturer’s generally long lead time requirements. The increase in drug manufacturing expenses for the three months ended March 31, 2017 compared to the three months ended March 31, 2016 was due to additional work related to optimization of the manufacturing process for our VDAs.
Other expenses include facility related expenses which were comparable in the 2017 and 2016 periods.
Our FOCUS study of CA4P in platinum-resistant ovarian cancer ison-going, and we are adding clinical trial sites, enrolling additional patients and continuing to treat existing patients. As a result, we expect research and development expenses to continue to increase in 2017, particularly for clinical studies, subject to our ability to secure sufficient funding to continue these studies.
General and administrative expenses
General and administrative expenses decreased for the three months ended March 31, 2017 compared to the three months ended March 31, 2016 primarily due to lower consulting and professional services. The table below summarizes the most significant components of our general and administrative expenses for the periods indicated and the amount and percentage change in these components (in thousands):
| Three months ended March 31, | Change | |||||||||||||||
| 2017 | 2016 | Amount | % | |||||||||||||
Employee compensation and related | $ | 527 | $ | 588 | $ | (61 | ) | -10 | % | |||||||
Stock-based compensation | 135 | 104 | 31 | 30 | % | |||||||||||
Consulting and professional services | 371 | 577 | (206 | ) | -36 | % | ||||||||||
Other | 89 | 103 | (14 | ) | -14 | % | ||||||||||
|
|
|
|
|
|
|
| |||||||||
Total general and administrative | $ | 1,122 | $ | 1,372 | $ | (250 | ) | -18 | % | |||||||
|
|
|
|
|
|
|
| |||||||||
Employee compensation and related expenses decreased for the three months ended March 31, 2017 compared to the three months ended March 31, 2016 due to lower estimated expenses for employee bonuses, less travel and lower net amount of vacation earned.
The increase in employee stock-based compensation for the three months ended March 31, 2017 compared to the three months ended March 31, 2016 was due toone-year initial cliff vesting of stock options granted in March 2016, resulting in a reduction to the estimated forfeiture rates for this tranche, which increases expense, and the earlier timing of employee options grants during 2017.
Consulting and professional services expenses decreased for the three months ended March 31, 2017 due to incurrence of significantly higher market research costs during the three months ended March 31, 2016.
Other expenses, which include facility related expenses, insurance expenses and taxes that are not based on income, decreased for the three month period ended March 31, 2017 compared to the three month period ended March 31, 2016 due to lower fees paid in several different areas, none of which were individually significant.
We expect general and administrative expenses to increase in 2017 to support our planned increase in clinical development activities, as well as for additional business development and investor relations efforts, subject to our ability to secure sufficient funding to continue these activities.
LIQUIDITY AND CAPITAL RESOURCES
We are currently developing two investigational drugs, both VDAs, for the treatment of cancer and currently have no sources of revenue to support the development costs for these investigational drugs. Accordingly, we measure liquidity by the cash and other capital we have available to fund our operations, which are primarily focused on the advancement of our drug candidates. To date, we have financed our operations principally through proceeds received from the sale of equity. We have experienced net losses in each year since our inception, and negative cash flows from operations in nearly every year. As of March 31, 2017, we had an accumulated deficit of over $282 million, including a net loss of approximately $4.0 million for the first quarter of 2017 and a net loss of $13.7 million for the year ended December 31, 2016. As of March 31, 2017, we held cash, cash equivalents and short-term investments of approximately $8.3 million, which we expect to be sufficient to fund our operations into approximately October 2017. If we are unable to secure additional funding prior to that date, we may be required to scale back or conclude our development activities altogether.
We will require additional capital before we can complete all planned clinical trials and development of CA4P and OXi4503. Additional funding may not be available to us on acceptable terms, or at all. If we are unable to access additional funds when needed we may not be able to continue the development of our product candidates or we could be required to delay, scale back or eliminate some or all of our development programs and operations. Any additional equity financing, if available, may not be available on favorable terms and would be dilutive to our current stockholders. Debt financing, if available, may involve restrictive covenants and could also be dilutive to our current stockholders. If we are able to access funds through collaborative or licensing arrangements, we may be required to relinquish rights to some of our technologies or product candidates that we would otherwise seek to develop or commercialize on our own, on terms that are not favorable to us.
12
Our ability to access capital when needed is not assured and, if access is not achieved on a timely basis, will materially harm our business, financial condition and results of operations.
If we are able to secure additional funding to continue our operations, we expect to incur significant additional costs and expenses over at least the next several years as a result of our plans to develop VDAs for the treatment of cancer, including continuing our existing clinical trials as well as conducting new, additional clinical trials and anticipated research and development expenditures. We anticipate that our development will include continuing our current clinical trials as well as new clinical trials and additional research and development expenditures.
Critical Accounting Policies and Significant Judgments and Estimates
There have been no changes to our critical accounting policies and significant judgments and estimates from our Annual Report on Form10-K for the year ended December 31, 2016.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
There have been no changes to our market risks from our Annual Report on Form10-K for the year ended December 31, 2016.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
The SEC requires that as of the end of the period covered by this Quarterly Report onForm 10-Q, the Chief Executive Officer (CEO) and the Chief Financial Officer (CFO) evaluate the effectiveness of the design and operation of our disclosure controls and procedures (as defined inRules 13a-15(e) and15d-15(e)) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, and report on the effectiveness of the design and operation of our disclosure controls and procedures. Based upon that evaluation, our CEO and CFO concluded that our disclosure controls and procedures were effective, as of March 31, 2017, to ensure that we record, process, summarize and report the information we must disclose in reports that we file or submit under the Exchange Act, within the time periods specified in the SEC’s rules and forms, and is accumulated and communicated to our management, including our CEO and CFO, as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting, identified in connection with the evaluation of such control that occurred during the last fiscal quarter, which have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Important Considerations
The effectiveness of our disclosure controls and procedures and our internal control over financial reporting is subject to various inherent limitations, including cost limitations, judgments used in decision making, assumptions about the likelihood of future events, the soundness of our systems, the possibility of human error, and the risk of fraud. Moreover, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions and the risk that the degree of compliance with policies or procedures may deteriorate over time. Because of these limitations, there can be no assurance that any system of disclosure controls and procedures or internal control over financial reporting will be successful in preventing all errors or fraud or in making all material information known in a timely manner to the appropriate levels of management.
Not applicable.
There have been no material changes to the risk factors as described in our Annual Report on Form10-K for the year ended December 31, 2016.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
None.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
None.
None.
13
| Incorporated by Reference | ||||||||||
Exhibit | Description | Form | Filing Date | Exhibit | Filed | |||||
10.1@ | Mateon Therapeutics, Inc. 2017 Equity Incentive Plan. | 8-K | 01/13/2017 | 10.1 | ||||||
10.2@ | Form of Option Agreement under Mateon Therapeutics, Inc. 2017 Equity Incentive Plan. | 8-K | 01/13/2017 | 10.2 | ||||||
10.3@ | Amended and Restated Mateon Therapeutics, Inc. 2015 Equity Incentive Plan. | 8-K | 01/13/2017 | 10.3 | ||||||
10.4@ | Amended and Restated Mateon Therapeutics, Inc. 2005 Stock Plan. | 8-K | 01/13/2017 | 10.4 | ||||||
31.1 | Certification of Chief Executive Officer pursuant to Rule13a-14(a) and15d-14(a). | x | ||||||||
31.2 | Certification of Chief Financial Officer pursuant to Rule13a-14(a) and15d-14(a). | x | ||||||||
32.1 | Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | x | ||||||||
101 | The following materials from Mateon Therapeutics, Inc.’s Quarterly Report on Form10-Q for the quarter ended March 31, 2017, formatted in XBRL (eXtensible Business Reporting Language): (i) Condensed Balance Sheets at March 31, 2017 and December 31, 2016, (ii) Condensed Statements of Comprehensive Loss for the three months ended March 31, 2017 and 2016, (iii) Condensed Statements of Cash Flows for the three months ended March 31, 2017 and 2016, and (iv) Notes to Condensed Financial Statements | x | ||||||||
@ Management contract or compensatory plan or arrangement.
14
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Mateon Therapeutics, Inc. (Registrant) | ||||||
| Date: May 8, 2017 | By: | /s/ William D. Schwieterman | ||||
| William D. Schwieterman | ||||||
Chief Executive Officer (Principal Executive Officer) | ||||||
| Date: May 8, 2017 | By: | /s/ Matthew M. Loar | ||||
| Matthew M. Loar | ||||||
Chief Financial Officer (Principal Financial Officer) | ||||||
15